Table 1

A total of six studies, collectively reporting on the results of 567 patients, were used for meta-analysis. these included studies of anti-PD1 therapy (nivolumab and pembrolizumab), anti-PD-L1 therapy (duralumab), and anti-CTLA-4 therapy (ipilimumab and tremelimumab). Across the studies, clinical activity was observed across both virally infected and uninfected patients

Study nameUninfectedHCV, HBV, or co-infectionReference
ResponsesTotal treatedORRResponsesTotal treatedORR
Nivolumab (CheckMate 040)251130.221171010.168El-Khoueiry AB et al 1
Checkmate 040
5330.152361080.333Yau T et al
Pembrolizumab (Keynote 224)13640.2035390.128Zhu AX et al 2
Durvalumab+tremelimumab6200.30200Kelley RK et al 41
Durvalumab2220.0912180.111Wainberg ZA et al 42
Pembrolizumab4170.2355120.417Feun LG et al 43
  • HBV, hepatitis B virus; HCV, hepatitis C virus; ORR, objective response rate.